Lenalidomide Capsule
Product Images NDC 63304-042

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 63304-042). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Image 02)

A Kaplan-Meier survival curve chart comparing progression-free survival (in months) among three treatment groups labeled Rd Continuous, Rd18, and MPT. The y-axis represents survival probability in percentage, and the x-axis shows progression-free survival in months. The chart includes hazard ratios with confidence intervals, a logrank p-value, and a table of the number of subjects at risk over time for each group.*

FDA Label Image

Image 2 (Image 03)

A Kaplan-Meier survival curve chart depicting overall survival probability (%) over time (months) for Lenalidomide treatment regimens: Rd Continuous, Rd18, and MPT. The chart shows survival probabilities for each regimen with hazard ratios and confidence intervals listed. Number of subjects at risk and overall survival events for each group are provided below the graph.*

FDA Label Image

Label 1 (Label 1)

Lenalidomide Capsules 5 mg oral capsule label from Sun Pharmaceutical Industries, Inc. The label includes dosing instructions and a warning about potential human birth defects. The package contains 28 capsules and displays the NDC number 63304-042-27 with a barcode and space for serialization.*

FDA Label Image

Label 2 (Label 2)

Label for Lenalidomide Capsules 10 mg by Sun Pharmaceutical Industries, Inc. The label includes a warning for potential human birth defects and instructs to dispense the accompanying medication guide with each prescription. It is marked Rx only and indicates a package containing 28 capsules. Storage instructions and manufacturing details are also present.*

FDA Label Image

Label 3 (Label 3)

The image shows a packaging label for Lenalidomide Capsules, 15 mg strength, oral capsule form, supplied in a container of 21 capsules. The label includes a warning about potential human birth defects and instructions to dispense the accompanying Medication Guide. The labeler is Sun Pharmaceutical Industries, Inc., and regulatory and storage information is visible, along with a barcode.*

FDA Label Image

Label 4 (Label 4)

Lenalidomide Capsules 25 mg oral capsules label from Sun Pharmaceutical Industries, Inc. The label includes a warning about potential human birth defects and instructions to dispense the medication guide to each patient. It states the package contains 21 capsules and includes storage conditions and the barcode. The label is marked Rx only.*

FDA Label Image

Spl-lenalidomdie-structure (Spl Lenalidomdie Structure)

Chemical structure diagram of lenalidomide, showing its molecular configuration with rings including amide and lactam groups.*

FDA Label Image

Spl-lenalidomide-image 08 (Spl Lenalidomide Image 08)

A Kaplan-Meier survival curve showing the estimate of time to progression in months for subjects in MM Study 2. The graph compares the proportion of subjects over time between two groups: lenalidomide/Dex (blue line) and Placebo/Dex (black line). The hazard ratio (HR) with 95% confidence interval and Log Rank p-value are indicated, highlighting statistically significant differences between groups.*

FDA Label Image

Spl-lenalidomide-image 09 (Spl Lenalidomide Image 09)

A Kaplan-Meier survival curve chart comparing progression-free survival probabilities over 48 months between two groups: one receiving Rituximab plus Lenalidomide and the other receiving Rituximab plus placebo. The x-axis represents progression-free survival in months, and the y-axis represents survival probability. Below the graph is a table showing the number of subjects at risk at different time points.*

FDA Label Image

Spl-lenalidomide-image 4 (Spl Lenalidomide Image 4)

A Kaplan-Meier survival curve comparing progression-free survival between Lenalidomide and Placebo groups over months. The y-axis represents survival probability, and the x-axis shows time in months up to 108. The Lenalidomide group (blue solid line) shows better survival probability than placebo (red dashed line). A table below the graph displays the number of subjects at risk over time for each group.*

FDA Label Image

Spl-lenalidomide-image 5 (Spl Lenalidomide Image 5)

A Kaplan-Meier survival curve illustrating time to progression in months for a multiple myeloma (MM) study. The graph compares two groups: one treated with lenalidomide plus dexamethasone and the other with placebo plus dexamethasone. The y-axis shows the proportion of subjects, and the x-axis shows time to progression up to 30 months. The lenalidomide/Dex group shows a higher proportion of subjects without progression over time compared to placebo/Dex.*

FDA Label Image

Spl-lenalidomide-image-01 (Spl Lenalidomide Image 01)

A Kaplan-Meier curve chart showing progression-free survival over months comparing Lenalidomide and placebo. The graph includes two survival curves—one for Lenalidomide and one for placebo—with corresponding median survival times and hazard ratio with confidence intervals. The chart also displays the number of subjects at risk at various time points for both treatment groups and the count of progression-free survival events.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.